Catalyst
Slingshot members are tracking this event:
Vertex (VRTX) Announces New Drug Submission for TRIKAFTA Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
VRTX |
|
|
Additional Information
"We are pleased this submission has been accepted for Priority Review by Health Canada, and we anticipate this accelerated review process will enable access for patients as early as possible," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 28, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cystic Fibrosis, Trifakta